Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.00% $1.650
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 54.96 mill |
EPS: | -2.36 |
P/E: | -0.700 |
Earnings Date: | Mar 24, 2024 |
SharesOutstanding: | 33.31 mill |
Avg Daily Volume: | 0.378 mill |
RATING 2024-03-27 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.700 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.12x |
Company: PE -0.700 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.754 (-54.32%) $-0.896 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 1.576 - 1.724 ( +/- 4.48%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-28 | Hall Ashley | Sell | 15 625 | Stock option (right to buy) |
2023-08-28 | Hall Ashley | Buy | 15 625 | Common Stock |
2023-08-28 | Hall Ashley | Sell | 15 625 | Common Stock |
2023-07-26 | Grey Michael G | Sell | 50 000 | Common Stock |
2023-06-23 | Novo Holdings A/s | Sell | 100 000 | Common Stock |
INSIDER POWER |
---|
50.37 |
Last 95 transactions |
Buy: 16 929 845 | Sell: 55 923 583 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.650 (0.00% ) |
Volume | 0.0441 mill |
Avg. Vol. | 0.378 mill |
% of Avg. Vol | 11.68 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:30 | sell | $1.650 | N/A | Active |
---|
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.